Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

Executive Summary

A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles

You may also be interested in...



DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost

The House Appropriations Committee opted for using federal money, rather than fees from industry, to finance speedier FDA review of direct-to-consumer television ads when it approved a $1.7 billion fiscal year 2008 funding package for the agency July 19

DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost

The House Appropriations Committee opted for using federal money, rather than fees from industry, to finance speedier FDA review of direct-to-consumer television ads when it approved a $1.7 billion fiscal year 2008 funding package for the agency July 19

DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan

FDA expects to charge companies $83,000 per advertisement under a pre-review program included as part of the agency's proposal for renewal of the prescription drug user fee program

Related Content

UsernamePublicRestriction

Register

PS047819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel